vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Repay Holdings Corp (RPAY). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $78.6M, roughly 1.1× Repay Holdings Corp). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 0.4%). Repay Holdings Corp produced more free cash flow last quarter ($23.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -1.3%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Repay Holdings Corp is a leading payment technology provider delivering integrated end-to-end payment processing solutions for businesses across North America. Its offerings include credit/debit card processing, ACH transfer services, POS system integrations and digital payment tools, serving retail, healthcare, automotive and e-commerce segments to help clients streamline transaction workflows and boost operational efficiency.
IOVA vs RPAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $78.6M |
| Net Profit | — | $-140.1M |
| Gross Margin | 67.4% | 74.2% |
| Operating Margin | -84.7% | -182.2% |
| Net Margin | — | -178.3% |
| Revenue YoY | 17.7% | 0.4% |
| Net Profit YoY | — | -3304.1% |
| EPS (diluted) | — | $-1.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $78.6M | ||
| Q3 25 | $67.5M | $77.7M | ||
| Q2 25 | $60.0M | $75.6M | ||
| Q1 25 | $49.3M | $77.3M | ||
| Q4 24 | $73.7M | $78.3M | ||
| Q3 24 | $58.6M | $79.1M | ||
| Q2 24 | $31.1M | $74.9M | ||
| Q1 24 | $715.0K | $80.7M |
| Q4 25 | — | $-140.1M | ||
| Q3 25 | $-91.3M | $-6.4M | ||
| Q2 25 | $-111.7M | $-102.3M | ||
| Q1 25 | $-116.2M | $-7.9M | ||
| Q4 24 | — | $-4.1M | ||
| Q3 24 | $-83.5M | $3.2M | ||
| Q2 24 | $-97.1M | $-4.1M | ||
| Q1 24 | $-113.0M | $-5.2M |
| Q4 25 | 67.4% | 74.2% | ||
| Q3 25 | 43.0% | 74.4% | ||
| Q2 25 | 5.5% | 75.7% | ||
| Q1 25 | -0.8% | 75.9% | ||
| Q4 24 | 68.7% | 76.3% | ||
| Q3 24 | 46.2% | 77.8% | ||
| Q2 24 | -0.8% | 78.2% | ||
| Q1 24 | — | 76.2% |
| Q4 25 | -84.7% | -182.2% | ||
| Q3 25 | -140.7% | -3.9% | ||
| Q2 25 | -189.8% | -138.7% | ||
| Q1 25 | -245.8% | -4.7% | ||
| Q4 24 | -117.5% | -1.5% | ||
| Q3 24 | -152.1% | -0.9% | ||
| Q2 24 | -327.6% | -4.6% | ||
| Q1 24 | -16464.6% | -3.1% |
| Q4 25 | — | -178.3% | ||
| Q3 25 | -135.3% | -8.3% | ||
| Q2 25 | -186.2% | -135.2% | ||
| Q1 25 | -235.5% | -10.3% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | -142.7% | 4.1% | ||
| Q2 24 | -312.2% | -5.4% | ||
| Q1 24 | -15800.8% | -6.5% |
| Q4 25 | — | $-1.68 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | $-0.33 | $-1.15 | ||
| Q1 25 | $-0.36 | $-0.09 | ||
| Q4 24 | $-0.24 | $-0.04 | ||
| Q3 24 | $-0.28 | $0.03 | ||
| Q2 24 | $-0.34 | $-0.04 | ||
| Q1 24 | $-0.42 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $115.7M |
| Total DebtLower is stronger | — | $280.1M |
| Stockholders' EquityBook value | $698.6M | $484.4M |
| Total Assets | $913.2M | $1.2B |
| Debt / EquityLower = less leverage | — | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $115.7M | ||
| Q3 25 | $300.8M | $95.7M | ||
| Q2 25 | $301.2M | $162.6M | ||
| Q1 25 | $359.7M | $165.5M | ||
| Q4 24 | $323.8M | $189.5M | ||
| Q3 24 | $397.5M | $168.7M | ||
| Q2 24 | $412.5M | $147.1M | ||
| Q1 24 | $356.2M | $128.3M |
| Q4 25 | — | $280.1M | ||
| Q3 25 | — | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | — | $496.8M | ||
| Q3 24 | — | $496.2M | ||
| Q2 24 | — | $435.6M | ||
| Q1 24 | — | $434.9M |
| Q4 25 | $698.6M | $484.4M | ||
| Q3 25 | $702.3M | $616.9M | ||
| Q2 25 | $698.5M | $633.7M | ||
| Q1 25 | $767.9M | $755.7M | ||
| Q4 24 | $710.4M | $761.3M | ||
| Q3 24 | $773.5M | $754.7M | ||
| Q2 24 | $768.5M | $815.4M | ||
| Q1 24 | $680.0M | $813.8M |
| Q4 25 | $913.2M | $1.2B | ||
| Q3 25 | $904.9M | $1.3B | ||
| Q2 25 | $907.4M | $1.4B | ||
| Q1 25 | $966.7M | $1.5B | ||
| Q4 24 | $910.4M | $1.6B | ||
| Q3 24 | $991.1M | $1.6B | ||
| Q2 24 | $964.3M | $1.5B | ||
| Q1 24 | $869.8M | $1.5B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.65× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $23.3M |
| Free Cash FlowOCF − Capex | $-61.9M | $23.2M |
| FCF MarginFCF / Revenue | -71.3% | 29.6% |
| Capex IntensityCapex / Revenue | 10.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $90.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $23.3M | ||
| Q3 25 | $-78.7M | $32.2M | ||
| Q2 25 | $-67.4M | $33.1M | ||
| Q1 25 | $-103.7M | $2.5M | ||
| Q4 24 | $-73.3M | $34.3M | ||
| Q3 24 | $-59.0M | $60.1M | ||
| Q2 24 | $-98.4M | $31.0M | ||
| Q1 24 | $-122.3M | $24.8M |
| Q4 25 | $-61.9M | $23.2M | ||
| Q3 25 | $-89.5M | $32.1M | ||
| Q2 25 | $-74.9M | $33.0M | ||
| Q1 25 | $-109.9M | $2.4M | ||
| Q4 24 | $-77.5M | $34.0M | ||
| Q3 24 | $-61.3M | $59.8M | ||
| Q2 24 | $-98.9M | $30.5M | ||
| Q1 24 | $-126.5M | $24.7M |
| Q4 25 | -71.3% | 29.6% | ||
| Q3 25 | -132.7% | 41.3% | ||
| Q2 25 | -124.9% | 43.6% | ||
| Q1 25 | -222.8% | 3.0% | ||
| Q4 24 | -105.1% | 43.5% | ||
| Q3 24 | -104.6% | 75.6% | ||
| Q2 24 | -317.9% | 40.7% | ||
| Q1 24 | -17685.3% | 30.6% |
| Q4 25 | 10.7% | 0.1% | ||
| Q3 25 | 16.1% | 0.2% | ||
| Q2 25 | 12.4% | 0.1% | ||
| Q1 25 | 12.6% | 0.2% | ||
| Q4 24 | 5.7% | 0.3% | ||
| Q3 24 | 3.9% | 0.3% | ||
| Q2 24 | 1.4% | 0.6% | ||
| Q1 24 | 583.4% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 18.52× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
